Lorenzen, S., Götze, T. O., Thuss-Patience, P., Biebl, M., Homann, N., Schenk, M., . . . Al-Batran, S. (2024). Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: Interim results from the randomized, multicenter, phase II/III DANTE/IKF-s633 trial. Journal of clinical oncology, 42(4), . https://doi.org/10.1200/JCO.23.00975
Chicago-Zitierstil (17. Ausg.)Lorenzen, Sylvie, et al. "Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results from the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial." Journal of Clinical Oncology 42, no. 4 (2024). https://doi.org/10.1200/JCO.23.00975.
MLA-Zitierstil (9. Ausg.)Lorenzen, Sylvie, et al. "Perioperative Atezolizumab Plus Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel for Resectable Esophagogastric Cancer: Interim Results from the Randomized, Multicenter, Phase II/III DANTE/IKF-s633 Trial." Journal of Clinical Oncology, vol. 42, no. 4, 2024, https://doi.org/10.1200/JCO.23.00975.